Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:54 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 12,626 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period A Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

NCT01204112
View directory record Official record
Conditions
Healthy
Interventions
Tasocitinib (CP-690,550) plus Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 22, 2010 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine

NCT04485702
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam injection, Ketamine Injectable Product, MELT-100
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Nov 1, 2026, 5:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study

NCT03339245
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Fructose Solution (75 Grams), Glucose Solution (75 grams)
Other
Lead sponsor
Rockefeller University
Other
Eligibility
45 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 1 Interventional

A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer

NCT00736372
View directory record Official record
Conditions
Metastatic Cancer, Advanced Cancer
Interventions
PX-12
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Greenville, South Carolina • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Nov 1, 2026, 5:54 AM EST
Active, not recruiting Early Phase 1 Interventional

Bladder Preservation or Cystectomy for MIBC

NCT07821177
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
Interventions
Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 3 Interventional Results available

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

NCT02585895
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Biological · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Nov 1, 2026, 5:54 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

NCT05203939
View directory record Official record
Conditions
Retinitis Pigmentosa, Leber Congenital Amaurosis
Interventions
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
Drug
Lead sponsor
Ocugen
Industry
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851212
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 1 Interventional

CCI-779 in Treating Patients With Advanced Solid Tumors

NCT00003712
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
temsirolimus
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
2
States / cities
Rochester, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Nov 1, 2026, 5:54 AM EST
Completed Not applicable Interventional Results available

Symptom Management Implementation of Patient Reported Outcomes in Oncology

NCT03850912
View directory record Official record
Conditions
Other Cancer, Gastrointestinal Cancer, Thoracic Cancer, Gynecologic Cancer
Interventions
Stakeholder Survey (Control Period), Stakeholder Survey (Intervention Period), Qualitative Interview, SASS Questionnaire, eSyM
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42,808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
Portland, Maine • Boston, Massachusetts • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Nov 1, 2026, 5:54 AM EST
Terminated Phase 3 Interventional Results available

Vortioxetine to Prevent Return of Symptoms in Children With Depression

NCT05014919
View directory record Official record
Conditions
Depression
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Atlanta, Georgia • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 2 Interventional Results available

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

NCT05323656
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Setanaxib, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Calliditas Therapeutics Suisse SA
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Miami Beach, Florida • City of Saint Peters, Missouri • Creve Coeur, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Nov 1, 2026, 5:54 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Oxytocin Aging Study

NCT02069431
View directory record Official record
Conditions
Inflammation
Interventions
Intranasal Oxytocin spray, Intranasal Placebo spray
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
55 Years to 100 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 2 Interventional Results available

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

NCT02633137
View directory record Official record
Conditions
Mantle Cell Lymphoma, Untreated
Interventions
Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Biology and Experience of Eating in Women With Obesity

NCT02805972
View directory record Official record
Conditions
Obesity
Interventions
Naloxone, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 1, 2026, 5:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

(YMP) Young Moms Program

NCT05082857
View directory record Official record
Conditions
Chronic Toxic Stress, Developmental/ Behavioral Regression in Young Children
Interventions
"traditional" Parents as Teachers (PAT), "hybrid" PAT model
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 2 Interventional Results available

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

NCT01685801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo-matched-to-ivacaftor tablet
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Nov 1, 2026, 5:54 AM EST
Terminated Phase 1 Interventional

Safety Study of Multikine in the Treatment of Perianal Warts

NCT02115919
View directory record Official record
Conditions
Condyloma
Interventions
Leukocyte Interleukin, Injection 200IU, Leukocyte Interleukin, injection 400IU
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Nov 1, 2026, 5:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Four-Week Oral Malodor and Clinical Safety for a Concentrated Cosmetic Mouthwash

NCT06479096
View directory record Official record
Conditions
Oral Malodor
Interventions
Brush / Espresso Mild Prototype, Brush / Espresso Intense Prototype, Brush / Fresh Breath Oral Rinse, Brush / Hydroalcohol
Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years to 99 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Nov 1, 2026, 5:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Opaque Bottle Study

NCT03711370
View directory record Official record
Conditions
Opaque Bottles, Conventional, Clear Bottles
Interventions
Clear Bottle, Opaque Bottle
Other
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
0 Years to 40 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Nov 1, 2026, 5:54 AM EST
Completed Phase 1 Interventional

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805
View directory record Official record
Conditions
Pulmonary/Respiratory Diseases
Interventions
Placebo, AZD5634
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Nov 1, 2026, 5:54 AM EST
Withdrawn Phase 2 Interventional

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

NCT05198362
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Placebo, Tesomet
Other · Drug
Lead sponsor
Saniona
Industry
Eligibility
13 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Nov 1, 2026, 5:54 AM EST
Recruiting Not applicable Interventional

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

NCT06939686
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Interventions
Miro3D Wound Matrix, Standard of Care (SOC)
Device · Other
Lead sponsor
Reprise Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Coconut Creek, Florida • Tamarac, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 1, 2026, 5:54 AM EST